Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 9/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.36 |
| ▸ | PAK1 | Q13153 | 11/20 | 0.35 |
| ▸ | KHK | P50053 | 1/20 | 0.33 |
| ▸ | IDH2 | P48735 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3924580 | 0.86 | LRRK2 (0.40) | LRRK2 | |
| SCHEMBL3923615 | 0.81 | PAK1 (0.40) | PAK4PAK1IDH2IRAK4 | |
| SCHEMBL3924301 | 0.79 | PAK4 (0.39) | PAK4PAK1IDH2IRAK4 | |
| SCHEMBL3929260 | 0.78 | PAK4 (0.38) | PAK4PAK1IDH2IRAK4 | |
| SCHEMBL3920930 | 0.78 | JAK2 (0.44) | — | |
| SCHEMBL3932218 | 0.75 | DKK1 (0.36) | PAK4PAK1KHK | |
| SCHEMBL3928058 | 0.71 | RBP4 (0.38) | KHK | |
| SCHEMBL916719 | 0.71 | POLB (0.36) | PAK4IDH2 | |
| SCHEMBL1722967 | 0.70 | JAK2 (0.42) | PAK4IDH2 | |
| SCHEMBL3922462 | 0.70 | PAK4 (0.31) | PAK4PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2051980-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-02-26 | — | — | EP | disclosed |
| US-7531539-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-12 | — | — | US | disclosed |
| EP-2051980-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-04-29 | — | — | EP | disclosed |
| WO-2008021924-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | JAK2, NTRK2, NTRK3 | PAK4 837/4885LRRK2 937/4885PAK1 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.